Updates are available Correction dated 2025-08-21
Click to view Correction: https://doi.org/10.1007/s40519-025-01776-7
-
Authors
Barazzoni, Rocco
Buscemi, Silvio
Busetto, Luca
Sbraccia, Paolo
Bo, Simona
Cereda, Emanuele
Chianelli, Marco
Chiappetta, Sonja
Dalle Grave, Riccardo
de Caro, Walter
Docimo, Giovanni
Galloro, Giuseppe
Iannone, Primiano
Leonetti, Frida
Lisso, Fabrizia
Manca, Maria Caterina
Medea, Gerardo
Merli, Manuela
Moretti, Anna Maria
Navarra, Giuseppe
Pagotto, Uberto
Paolini, Barbara
Papa, Giovanni
Perrotta, Nicola
Pession, Andrea
Pilone, Vincenzo
Provenzano, Vincenzo
Rizzo, Cecilia Ricciardi
Santomauro, Maurizio
Garcia, Cristina Segura
Spandonaro, Federico
Sukkar, Samir
Todisco, Patrizia
Tuccinardi, Dario
Vania, Andrea
Vanzi, Valentina
Williams, Riccardo
Zani, Iris
Ragghianti, Benedetta
Silverii, Giovanni Antonio
Monami, Matteo
,
-
Funding
Funding for this research was provided by:
Università degli Studi di Trieste
- License Information
-
More Information
Article History
Received: 21 February 2025
Accepted: 28 March 2025
First Online: 4 June 2025
Change Date: 6 February 2026
Change Type: Update
Change Details: The given and family name of one of the co-author was corrected.
Change Date: 21 August 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40519-025-01776-7
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors.
: SB has received consultancy or speaking fees or research direct or indirect contributions from Novo Nordisk, Eli Lilly, Boehringer, Pfizer, Dompè, Bruno farmaceutici, Recordati rare diseases, Therascience, Merieux; LB has received consultancy fees from Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Pfizer, Roche, Regeneron and Bruno Farmaceutici and speaking fees from Rythms Pharmaceuticals and Pronokal; EM has received consultancy fees from Merck and Novartis speaking fees from Astra Zeneca, Bristol Myers Squibb, Boehringer-Ingelheim, Eli-Lilly, Merck, Novo Nordisk, Sanofi, and Novartis and research grants from Merck, Novartis, and Takeda. CC and LN have no relevant conflicts of interest to declare. MM has received speaking fees from Astra Zeneca, Bristol Myers Squibb, Boehringer-Ingelheim, Eli-Lilly, Merck, Novo Nordisk, Sanofi, and Novartis and research grants from Bristol Myers Squibb; PS received payment of honoraria and consulting fees from Boehringer Ingelheim, Chiesi, Novo Nordisk, Eli Lilly, Pfizer, and Roche as a member of advisory boards. All the other authors have no relevant COI to declare.
